Bedfont® Scientific Ltd., an innovative leader in the medical breath analysis industry with almost 50 years of experience, is pleased to be joining thousands of medical professionals at this year’s European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 on stand I03 to introduce its NObreath® and Gastrolyzer® series of non-invasive breath analyzers.
Image credit: Bedfont® Scientific Ltd.
The conference, which will be held from Friday 12th to Sunday 14th June in Turkiye, Istanbul, is widely recognized as the world’s largest and most influential conference dedicated to allergy and clinical immunology. Each year, thousands of clinicians, researchers, and health professionals from around the world come together to share new ideas, showcase innovations in diagnostics, and play a central role in advancing research, education, and patient care for allergic diseases such as asthma and food allergies.
Our attendance at the 2026 EAACI conference reflects our commitment to strengthening our global network. We look forward to connecting with like-minded organizations, sharing insights about our technology, and exploring new sales partnerships with those seeking innovative solutions. We see EAACI as an important opportunity to build relationships that will foster future growth in the field of allergy and immunology. ”
Jason Smith, Bedfont® CEO
The Bedfont® team is pleased to have Turkish distributor Teknikel on board to demonstrate fractional exhaled nitric oxide (FeNO) and hydrogen and methane breath testing (HMBT) technology, highlighting how these innovative tools can support improved diagnosis, monitoring, and management of respiratory and gastrointestinal conditions.
The team will be on display at stand I03. There, you’ll find the NObreath® FeNO device, which has been improving asthma care and management for over 15 years, providing objective insight into airway inflammation, a key driver of asthma symptoms. Additionally, the Gastrolyzer® series of HMBT devices has been supporting gastrointestinal testing for over 35 years, allowing clinicians to effectively tailor treatment.
For Bedfont®, this conference is invaluable not only to showcase our solutions, but also to engage with our partners and stakeholders as we continue to advance our technology and expand our global reach.
sauce:
Bedfont® Scientific Ltd.
